UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1193-9
Program Prior Authorization/Notification
Medication Somavert® (pegvisomant)
P&T Approval Date 7/2016, 7/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Somavert (pegvisomant) is a growth hormone receptor antagonist indicated for the treatment of
acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or
for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-
like growth factor-I (IGF-I) levels.1
2. Coverage Criteriaa:
A. Acromegaly
1. Initial Authorization
a. Somavert will be approved based on both of the following criteria:
(1) Diagnosis of acromegaly
-AND-
(2) One of the following:
(a) Inadequate response to one of the following:
i. Surgery
ii. Radiation therapy
-OR-
(b) Not a candidate for either of the following:
i. Surgery
ii. Radiation therapy
Authorization will be issued for 12 months.
2. Reauthorization
a. Somavert will be approved based on the following criterion:
(1) Documentation of positive clinical response to Somavert therapy
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Somavert [package insert]. New York, NY: Pfizer Inc.; July 2023.
Program Prior Authorization/Notification – Somavert® (pegvisomant)
Change Control
7/2016 New program
7/2017 Annual review. No changes to the program.
7/2018 Annual review. No changes to the program.
7/2019 Annual review. No changes to the program.
7/2020 Annual review. No changes to coverage criteria.
7/2021 Annual review. No changes to coverage criteria.
7/2022 Annual review. Added state mandate with no other changes to coverage
criteria. Reference updated.
7/2023 Annual review. No changes to coverage criteria.
7/2024 Annual review with no changes to coverage criteria. Updated
reference.
© 2024 UnitedHealthcare Services, Inc.
2